Literature DB >> 10655363

Multisite reproducibility of Etest for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.

G L Woods1, J S Bergmann, F G Witebsky, G A Fahle, B Boulet, M Plaunt, B A Brown, R J Wallace, A Wanger.   

Abstract

A multicenter study was conducted to assess the inter- and intralaboratory reproducibility of the Etest for susceptibility testing of the rapidly growing mycobacteria. The accuracy also was evaluated by comparing Etest results to those obtained by broth microdilution. Ten isolates (four of the Mycobacterium fortuitum group, three of Mycobacterium abscessus, and three of Mycobacterium chelonae) were tested against amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline, imipenem, and trimethoprim-sulfamethoxazole in each of four laboratories. At each site, isolates were tested three times on each of three separate days (nine testing events per isolate) using common lots of media and Etest strips. Interlaboratory agreement among MICs (i.e., mode +/- 1 twofold dilution) varied for the different drug-isolate combinations and overall was best for trimethoprim-sulfamethoxazole (75% for one isolate and 100% for all others), followed by doxycycline and ciprofloxacin. Interlaboratory agreement based on interpretive category also varied and overall was best for doxycycline (100% for all isolates), followed by trimethoprim-sulfamethoxazole and ciprofloxacin. Interlaboratory reproducibility among MICs was most variable for imipenem, and agreement by interpretive category was lowest for imipenem and amikacin. Modal Etest MICs agreed with those by broth microdilution only for doxycycline and the sulfonamides. For all other drugs, the modal MICs by the two methods differed by more than +/- 1 twofold dilution for one or more isolates. In all cases, the Etest MIC was higher and would have caused reports of false resistance. In summary, the Etest in this evaluation did not perform as well as broth microdilution for susceptibility testing of the rapidly growing mycobacteria. It was problematic for most species and drugs, primarily because of a trailing endpoint and/or high MICs compared to broth. Its use will necessitate further investigation, including determination of the optimal medium and incubation conditions and clarification of endpoint interpretation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10655363      PMCID: PMC86169     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Evaluation of Etest for rapid susceptibility testing of Mycobacterium chelonae and M. fortuitum.

Authors:  S E Hoffner; L Klintz; B Olsson-Liljequist; A Bolmström
Journal:  J Clin Microbiol       Date:  1994-08       Impact factor: 5.948

2.  Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.

Authors:  R J Wallace; B A Brown; G O Onyi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients.

Authors:  D E Griffith; W M Girard; R J Wallace
Journal:  Am Rev Respir Dis       Date:  1993-05

4.  Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.

Authors:  R J Wallace; V A Silcox; M Tsukamura; B A Brown; J O Kilburn; W R Butler; G Onyi
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

5.  Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin.

Authors:  R J Wallace; B A Brown; G O Onyi
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

6.  Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.

Authors:  J M Swenson; R J Wallace; V A Silcox; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

7.  Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution.

Authors:  J M Swenson; C Thornsberry; V A Silcox
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

8.  Etest for routine clinical antimicrobial susceptibility testing of rapid-growing mycobacteria isolates.

Authors:  F P Koontz; M E Erwin; M S Barrett; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1994-07       Impact factor: 2.803

9.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.

Authors:  B A Brown; R J Wallace; G O Onyi; V De Rosas; R J Wallace
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 10.  Disseminated infection with rapidly growing mycobacteria.

Authors:  C W Ingram; D C Tanner; D T Durack; G W Kernodle; G R Corey
Journal:  Clin Infect Dis       Date:  1993-04       Impact factor: 9.079

View more
  15 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.

Authors:  Barbara A Brown-Elliott; Jessica Killingley; Sruthi Vasireddy; Linda Bridge; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

3.  Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Authors:  Zofia Bakuła; Magdalena Modrzejewska; Lian Pennings; Małgorzata Proboszcz; Aleksandra Safianowska; Jacek Bielecki; Jakko van Ingen; Tomasz Jagielski
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing.

Authors:  Sylvaine Bastian; Nicolas Veziris; Anne-Laure Roux; Florence Brossier; Jean-Louis Gaillard; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

5.  Description of Mycobacterium conceptionense sp. nov., a Mycobacterium fortuitum group organism isolated from a posttraumatic osteitis inflammation.

Authors:  Toïdi Adékambi; Andréas Stein; Joseph Carvajal; Didier Raoult; Michel Drancourt
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

6.  Mycobacterium barrassiae sp. nov., a Mycobacterium moriokaense group species associated with chronic pneumonia.

Authors:  Toïdi Adékambi; Didier Raoult; Michel Drancourt
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

7.  Carbapenem susceptibility patterns for clinical isolates of Mycobacterium abscessus determined by the Etest method.

Authors:  Shingo Chihara; Geremy Smith; Cathy A Petti
Journal:  J Clin Microbiol       Date:  2009-12-16       Impact factor: 5.948

8.  Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases.

Authors:  Toshiyuki Harada; Yasushi Akiyama; Atsuyuki Kurashima; Hideaki Nagai; Kazunari Tsuyuguchi; Takashi Fujii; Syuichi Yano; Eriko Shigeto; Toshihiko Kuraoka; Akira Kajiki; Yoshihiro Kobashi; Fumio Kokubu; Atsuo Sato; Shiomi Yoshida; Tomotada Iwamoto; Hajime Saito
Journal:  J Clin Microbiol       Date:  2012-08-22       Impact factor: 5.948

9.  Report of two fatal cases of Mycobacterium mucogenicum central nervous system infection in immunocompetent patients.

Authors:  Toïdi Adékambi; Cedric Foucault; Bernard La Scola; Michel Drancourt
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

Review 10.  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.